Text size: AAA
Step into summer in the best shape of your life with these reports from Harvard Medical School.
Learn How

Start your exercise and fitness program and reap the benefits of being more fit, stronger and healthier!

Warmer weather is on the way and it's not too late to get in shape for the summer. These 3 reports can help you enjoy outdoor activities in the best shape of your life:

References for "The glutamate hypothesis for schizophrenia"

MAY 2009

Next Article:

Did you know?

You can get instant online access to all of the articles from the May 2009 issue of Harvard Mental Health Letter for only $5.

Already a subscriber? Login for complete instant access.

If you want a button/link to remove the box (not sure if you do or not...), it would look like this: Cancel

Buchanan RW, et al. "The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The Efficacy of Glutamatergic Agents for Negative Symptoms and Cognitive Impairments," American Journal of Psychiatry (Oct. 2007): Vol. 164, No. 10, pp. 1593–602. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17898352

Buchanan RW, et al. "Recent Advances in the Development of Novel Pharmacological Agents for the Treatment of Cognitive Impairments in Schizophrenia," Schizophrenia Bulletin (Sept. 2007): Vol. 33, No. 5, pp. 1120–30. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17641146

Coyle JT. "The Glutamatergic Dysfunction Hypothesis for Schizophrenia," Harvard Review of Psychiatry (Jan.–Feb. 1996): Vol. 3, No. 5, pp. 241–53. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9384954

Fell MJ, et al. "Evidence for the Role of Metabotropic Glutamate (mGlu)2 Not mGlu3 Receptors in the Preclinical Antipsychotic Pharmacology of the mGlu2/3 Receptor Agonist (-)-(1R,4S,5S,6S)-4-Amino-2-Sulfonylbicyclo[3.1.0]hexane-4,6-Dicarboxylic Acid (LY404039)," Journal of Pharmacology and Experimental Therapeutics (July 2008): Vol. 326, No. 1, pp. 209–17. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18424625

Ford JM, et al. "Neural Synchrony in Schizophrenia," Schizophrenia Bulletin (Sept. 2008): Vol. 34, No. 5, pp. 904–06. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18658126

Goff DC, et al. "Once-Weekly D-Cycloserine Effects on Negative Symptoms and Cognition in Schizophrenia: An Exploratory Study," Schizophrenia Research (Dec. 2008): Vol. 106, No. 2–3, pp. 320–07. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18799288

Goff DC. "Pharmacologic Implications of Neurobiological Models of Schizophrenia," Harvard Review of Psychiatry (Nov.–Dec. 2005): Vol. 13, No. 6, pp. 352–59. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16373329

Javitt DC, et al. "Recent Advances in the Phencyclidine Model of Schizophrenia," American Journal of Psychiatry (Oct. 1991): Vol. 148, No. 10, pp. 1301–08. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1654746

Krystal JH, et al. "Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses," Archives of General Psychiatry (March 1994): Vol. 51, No. 3, pp. 199–214. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8122957s

Lahti AC, et al. "Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia," Neuropsychopharmacology (Aug. 1995): Vol. 13, No. 1, pp. 9–19. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8526975

Mossner R, et al. "Further Evidence for a Functional Role of the Glutamate Receptor Gene GRM3 in Schizophrenia," European Neuropsychopharmacology (Oct. 2008): Vol. 18, No. 10, pp. 768–72. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18614340

Otto MW, et al. "Clinical Perspectives on the Combination of D-Cycloserine and Cognitive-Behavioral Therapy for the Treatment of Anxiety Disorders," CNS Spectrums (Jan. 2007): Vol. 12, No. 1, pp. 51–6, and 59–61. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17192764

Patil ST, et al. "Activation of mGlu2/3 Receptors as a New Approach to Treat Schizophrenia: A Randomized Phase 2 Clinical Trial," Nature Medicine (Sept. 2007): Vol. 13, No. 9, pp. 1102–07. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17767166

Tuominen HJ, et al. "Glutamatergic Drugs for Schizophrenia," Cochrane Database of Systematic Reviews (April 2006): Doc. No. CD003730. www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16625590

“Using D-Cycloserine to Enhance the Benefits of Cognitive Behavioral Therapy for Schizophrenia,” summary of NIMH study. ClinicalTrials.gov Identifier: NCT00742079.

Next Article: